Early diagnosis of infections

Patent metadata

Field	Value
Publication number	US-12055545-B2
Application number	US-202217717200-A
Country	US
Kind code	B2
Filing date	Apr 11, 2022
Priority date	Jul 10, 2016
Publication date	Aug 6, 2024
Grant date	Aug 6, 2024

Abstract

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

First claim

What is claimed is:

1. A method of treating a human subject showing symptoms of a pathogenic infection and exhibiting a level of interferon γ-induced protein (IP-10) above 160 pg/ml in a blood sample no more than two days following symptom onset, the method comprising administering to the subject a therapeutically effective amount of an antibiotic or antiviral agent, thereby treating the human subject.

2. The method of claim 1 , further comprising analyzing the level of TNF-related apoptosis-inducing ligand (TRAIL) in the sample prior to the treating.

3. The method of claim 1 , wherein said symptoms of a pathogenic infection comprise fever.

4. The method of claim 1 , wherein the sample is isolated from the subject no more than one day following symptom onset.

5. The method of claim 1 , wherein the sample is whole blood or a fraction thereof.

6. A method of diagnosing and treating a human subject showing symptoms of a pathogenic infection comprising:
(a) analyzing the amount of interferon γ-induced protein (IP-10) in a blood sample isolated from the subject no more than two days following symptom onset; and
(b) treating the subject with a therapeutically effective amount of an antibiotic or antiviral agent when the level of IP-10 is above 160 pg/ml, thereby treating the subject.

7. The method of claim 6 , wherein said IP-10 is measured using a lateral flow immunoassay.

8. The method of claim 6 , wherein said IP-10 is measured using an antibody which binds specifically to IP10.

9. The method of claim 8 , wherein said antibody is a monoclonal antibody.

10. The method of claim 6 , further comprising analyzing a level of a polypeptide selected from the group consisting of TNF-related apoptosis-inducing ligand (TRAIL), Interleukin 6 (IL-6) and Interleukin 1 receptor, type I (IL1RA).

11. The method of claim 6 , further comprising analyzing a level of a polypeptide selected from the group consisting of Interleukin 6 (IL-6), Interleukin 1 receptor, type I (IL1RA), C-reactive protein (CRP) and procalcitonin (PCT).

Assignees

• Memed Diagnostics Ltd

Inventors

• Eden Eran
• Oved Kfir
• Cohen-Dotan Assaf
• Navon Roy
• Boico Olga
• Paz Meital

Classifications

• G01N33/6869

  Interleukin · CPC title

• G01N33/56983

  Viruses · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• G01N2800/60

  Complex ways of combining multiple protein biomarkers for diagnosis · CPC title

• G01N33/5005

  involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025) · CPC title